Minerva Biotechnologies

Exploring the Space between Stem Cells and Cancers

  • Stems Cells & Reagents
  • Functionalized Nanoparticles
  • Cancer Therapeutics

Show me more

Latest Products

News

  • Minerva Biotechnologies granted worldwide license to iPS technology

    Minerva Biotechnologies granted worldwide license to iPS technology

    WALTHAM, Massachusetts and KYOTO, Japan, August 4, 2015 Minerva Biotechnologies and iPS Academia Japan, Inc. announced today that they have signed an agreement granting Minerva worldwide rights to use and commercialize the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Professor Shinya Yamanaka, MD, Ph.D., who won the Nobel Prize for […]

    Read More

  • Research Scientist

    Research Scientist

    Research Scientist Minerva Biotechnologies has openings for PhD level scientists. Desirable backgrounds include Biochemistry with experience in cell culture, cloning, protein engineering, protein expression, purification and characterization and Cancer Biology with experience in cell culture, assay development, animal models, xenograft experiments and tumor biology.  Excellent opportunity for creative scientists.  Good work ethic is a must.  […]

    Read More

  • Dr. Bamdad gives presentation at International Stem Cell Conference

    Dr. Bamdad gives presentation at International Stem Cell Conference

    Presented in Stockholm, Sweden June 25, 2015 at the Annual Meeting of the International Society of Stem Cell Researchers A PRIMITIVE GROWTH FACTOR IS SUFFICIENT TO INDUCE STABLE NAÏVE STATE HUMAN PLURIPOTENCY VIA A LIF- AND FGF-INDEPENDENT PATHWAY; REPROGRAMMING IN THIS NOVEL GROWTH FACTOR CONFERS SUPERIOR DIFFERENTIATION   Scientists have generated human stem cells that […]

    Read More